Ursinus College Alumni Journal, Spring 1940

Current comment: In memoriam, Matthew Beardwood • President\u27s page • On the campus: Founder\u27s Day; Temple University confers LL.D. upon President McClure; Former Metropolitan soprano added to Ursinus faculty; Speakers; State associations re-elect Ursinus executives; Meistersingers present musical programs in churches • Review of the Letters of John Chamberlain, edited by President McClure • Alumni Association nominees • Winter sports • Radiologists honor Dr. Pfahler • About ourselves • 70th annual Commencementhttps://digitalcommons.ursinus.edu/alumnijournal/1008/thumbnail.jp

EFFECTS OF TERNARY ADDITIONS OF ALUMINUM-35 w/o URANIUM ALLOYS

The effects of a number of ternary additions on the constitution, casting, and fabricating characteristics and the physical properties of aluminum- 35 wt.% uranium were investigated. Initial investigations were concerned with the effects of 3 at.% ternary additions on the microstructure and press-forging characteristics of the alloy. It was found that additions of this magnitude often introduced extrinsic phases in the alloy. At the 3 wt% level, additions of germanium, silicon, tin, or zirconium inhibited the formation of UAl/sub 4/ and thereby increased the extent of the aluminum matrix in the alloy. It was also noted that these additions decreased the pressures required for extruding, and the tin addition also improved the homogeneity of cast shapes. Lead and palladium also improved the homogeneity of the cast material; however, neither of these was an effective inhibitor of UAl/sub 4/ and free lead was detected in the alloy to which lead had been added as the ternary. From these studies it appears that tin and zirconium are as effective as silicon in enhancing the fabricating characteristics of rior when evaluated on the bases of casting qualities and recycling characteristics. (auth

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

To map presynaptic cholinergic terminal densities in normal aging (n = 36), Alzheimer's disease (AD) (n = 22), and Parkinson's disease (PD) (n = 15), we performed single-photon emission computed tomography using [ 123 I]iodoben-zovesamicol (IBVM), an in vivo marker of the vesicular acetylcholine transporter. We used coregistered positron emission tomography with [ 18 F]fluorodexyglucose for metabolic assessment and coregistered magnetic resonance imaging for atrophy assessment. In controls (age, 22–91 years), cortical IBVM binding declined only 3.7% per decade. In AD, cortical binding correlated inversely with dementia severity. In mild dementia, binding differed according to age of onset, but metabolism did not. With an onset age of less than 65 years, binding was reduced severely throughout the entire cerebral cortex and hippocapus (about 30%), but with an onset age of 65 years or more, binding reductions were restricted to temporal cortex and hippocampus. In PD without dementia, binding was reduced only in parietal and occipital cortex, but demented PD subjects had extensive cortical binding decreases similar to early-onset AD. We conclude that cholinergic neuron integrity can be monitored in living AD and PD patients, and that it is not so devastated in vivo as suggested by postmortem choline acetylransferase activity (50–80%).Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/50361/1/410400309_ftp.pd

IC‐P2‐074: Differentiating amnestic MCI converting to probable AD from stable amnestic MCI using FDG‐PET and an AD‐related hypometabolism overlap index

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152594/1/alzjjalz200805067.pd

Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation

Seeking antemortem markers to distinguish Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), we examined brain glucose metabolism of DLB and AD. Eleven DLB patients (7 Lewy body variant of AD [LBVAD] and 4 pure diffuse Lewy body disease [DLBD]) who had antemortem position emission tomography imaging and autopsy confirmation were compared to 10 autopsy-confirmed pure AD patients. In addition, 53 patients with clinically-diagnosed probable AD, 13 of whom later fulfilled clinical diagnoses of DLB, were examined. Autopsy-confirmed AD and DLB patients showed significant metabolic reductions involving parietotemporal association, posterior cingulate, and frontal association cortices. Only DLB patients showed significant metabolic reductions in the occipital cortex, particularly in the primary visual cortex (LBVAD −23% and DLBD −29% vs AD −8%), which distinguished DLB versus AD with 90% sensitivity and 80% specificity. Multivariate analysis revealed that occipital metabolic changes in DLB were independent from those in the adjacent parietotemporal cortices. Analysis of clinically-diagnosed probable AD patients showed a significantly higher frequency of primary visual metabolic reduction among patients who fulfilled later clinical criteria for DLB. In these patients, occipital hypometabolism preceded some clinical features of DLB. Occipital hypometabolism is a potential antemortem marker to distinguish DLB versus AD.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34886/1/1133_ftp.pd

P2‐037: Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s disease neuroimaging initiative

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152628/1/alzjjalz2008051118.pd